An interventional study of TEACH and Basic health education in ADRD, Alzheimer's Disease and Alzheimer's Disease and Alzheimer's Disease Related Dementias (AD/ADRD), sponsored by Rhode Island Hospital. Not yet recruiting at 1 site in United States. Open to participants aged 40 Years to 69 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-12.
Sponsored by Rhode Island Hospital · Not applicable, Interventional, and Prevention
Among 1,939 studies in Alzheimer Disease with a site in United States — 345 open to participants now, 445 under way, 40 of them phase 3. Alzheimer Disease · United States.
Among the 1,939 studies in Alzheimer Disease with a site in United States, this one is the 326th largest by planned enrollment of the 1,608 interventional ones that give a count, is one of 8 that started in 2027, is one of 608 with no phase, reaches primary completion later than 420 of the 444 other live ones, and was the 1,939th registered.
3,965 studies on the registry are indexed under Alzheimer Disease; 926 are open to participants now.
Browse Alzheimer Disease studies →345 of the 1,939 studies in Alzheimer Disease with a site in United States are open now. Recruiting first, the newest first:
National Institute on Aging (NIA) · Sites in United States
Ages 55–110 · Healthy volunteers
National Institute on Aging (NIA) · Sites in United States
Ages 65–120 · Healthy volunteers
Prevention Research Consortium Corp. · Sites in United States
Ages 55+ · Healthy volunteers
Hoffmann-La Roche · Sites in United States, Australia, France
Ages 50–90
University of Wisconsin, Madison · Sites in United States
Ages 60+ · Healthy volunteers
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 641 Alzheimer Disease studies recruiting now, 283 (44%) set no upper age limit and 54 (8%) stop at 75 or younger; 34 take children under 18; 283 take healthy volunteers.
This study: 40 Years to 69 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
1,939 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 371 · Phase 2 469 · Phase 3 230 · Phase 4 60
First in 1981; this study’s year is marked. 8 started in 2027.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 280 is above the median of 70 across 3,019 interventional studies indexed under Alzheimer Disease.
Median enrollment 73 across the 1,608 interventional studies, 160 across the 309 observational. Of the 1,377 that completed or were terminated, 590 (43%) have results posted.
This tab as a report to print or save as PDF → With an account.
731 of 1,939 have an industry lead sponsor. The 10 most frequent:
Rhode Island Hospital is the lead sponsor of 192 studies on the registry; 37 are open to participants now.
Of its 12 completed or terminated interventional studies of FDA-regulated products, 2 (17%) have results posted.
Rhode Island Hospital has 5 studies filed under Alzheimer Disease — fewer than ten, so there is no comparison to draw.
164 of the studies in Alzheimer Disease with a site in United States that are under way reach primary completion within a year, 6 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06585787Phase 3Karuna Therapeutics, Inc., a Bristol Myers Squibb companyA Study to Evaluate KarXT as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-4) | 2026-11-24 |
| NCT06126224Phase 3Karuna Therapeutics, Inc., a Bristol Myers Squibb companyA Study to Assess Efficacy and Safety of KarXT for the Treatment of Psychosis Associated With Alzheimer's Disease (ADEPT-2) | 2026-12-09 |
| NCT03860857Phase 3University of California, IrvineBiomarker Exploration in Aging, Cognition and Neurodegeneration | 2026-12-22 |
| NCT03887455Phase 3Eisai Inc.A Study to Confirm Safety and Efficacy of Lecanemab in Participants With Early Alzheimer's Disease | 2026-12-31 |
| NCT05980949Phase 3Karuna Therapeutics, Inc., a Bristol Myers Squibb companyOpen-Label Extension Study to Assess the Long-Term Safety and Tolerability of KarXT in Subjects With Psychosis Associated With Alzheimer's Disease (ADEPT-3) | 2027-09-07 |
Add all 164 to your calendar (.ics) → With an account.
Among the 1,939 studies in Alzheimer Disease with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This Stage II behavioral intervention development project will examine the efficacy of a multi-domain health behavior intervention for primary prevention of Alzheimer's disease and related dementias (ADRD) in middle age.
The 8-week, remotely-delivered TEACH intervention was designed to promote maintenance, not just initiation, of health behaviors that reduce risk for ADRD. This randomized controlled trial (N=140 per arm; 1:1 allocation) will examine the efficacy of TEACH versus basic health education alone at end of treatment (8 weeks) and 4- and 12-month follow-up. We will examine the efficacy of the intervention on a multidomain behavioral composite score and individual health behaviors related to dementia risk (Aim 1) and biological outcomes including metabolic syndrome severity and a proteomic dementia risk score (Aim 2). We will also examine behavioral mediators of treatment effects on biological outcomes (how the intervention works) and its possible moderators (who benefits the most; Aim 3).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Participants must have at least two of six dementia risk factors:
Participants must have suboptimal engagement in at least one core health behavior:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TEACH Intervention
Behavioral: TEACH
Basic Health Education
Behavioral: Basic health education
The TEACH intervention provides a personalized assessment of and education about ADRD risk factors and health belief traits that are evidence-based moderators of behavior change. The 8-week, remotely delivered group intervention educates participants about 16 modifiable risk factors for ADRD. TEACH includes a personalized goal-setting process and education about health beliefs that are barriers or facilitators of behavior change.
The basic health education is an 8-week, remotely delivered group intervention that educates participants about 16 modifiable risk factors for ADRD.
Multidomain behavioral composite
This multidomain behavioral composite score is an unweighted average of five individual health behaviors: physical activity, Mediterranean diet adherence, cognitive activity, sleep quality, and alcohol use. Z-scores (or robust z-scores based on median/median absolute deviation for non-normal variables) for each continuous component score at baseline are calculated. Individual measures include 7-day average of moderate/vigorous physical activity measured via wearable (physical activity, total sleep time), Mediterranean Diet Adherence Tool total score (diet), Florida Cognitive Activities Scale (cognitive activity), and average units of alcohol consumed in the past two weeks (alcohol).
Time frame: baseline, 2 months (end of treatment), 4 months, 12 months
Metabolic Syndrome Severity Score (MetS severity)
Race- and sex-specific weighted z-score based on confirmatory factor analysis from NHANES data (Gurka et al., 2012, 2014). MetS severity score is based on waist circumference, blood pressure, triglycerides, HDL cholesterol, and fasting plasma glucose
Time frame: baseline, 2 months (end of treatment), 4 months, 12 months
Dementia SomaSignal Test
Proteomic ADRD risk index that predicts 20-year risk of dementia from middle age
Time frame: baseline, 2 months (end of treatment), 12 months
Wearable measurement of moderate/vigorous physical activity minutes
7-day average of moderate to vigorous physical activity minutes, collected via wearable
Time frame: baseline, 2 months (end of treatment), 4 months, 12 months
Step count
7-day average step count, collected via wearable
Time frame: baseline, 2 months (end of treatment), 4 months, 12 months
Total sleep time
7-day average total sleep time, collected via wearable
Time frame: baseline, 2 months (end of treatment), 4 months, 12 months
Mediterranean Diet Adherence Tool
standardized assessment of adherence to the Mediterranean diet (self-report)
Time frame: baseline, 2 months (end of treatment), 4 months, 12 months
Florida Cognitive Activities Scale
standardized assessment of cognitive activities (self-report)
Time frame: baseline, 2 months (end of treatment), 4 months, 12 months
Consensus Sleep Diary
standardized assessment of sleep quantity and quality (self-report)
Time frame: baseline, 2 months (end of treatment), 4 months, 12 months
International Physical Activities Scale
standardized assessment of types and intensity of physical activity and sitting time that people do as part of their daily lives. This can be used to estimate total activity in MET-min/week and time spent sitting.
Time frame: baseline, 2 months (end of treatment), 4 months, 12 months
Perceived Threat of ADRD
perceived threat and susceptibility of Alzheimer's disease and related dementias (7-item Likert scale)
Time frame: baseline, 2 months (end of treatment), 4 months, 12 months
Dementia Awareness Questionnaire
standardized self-report measure of dementia knowledge, including knowledge of modifiable risk factors for ADRD
Time frame: baseline, 2 months (end of treatment), 4 months, 12 months
Motivation to Change Behavior for Dementia Risk Reduction (MOCHAD-10)
self-report measure of self-efficacy pertaining to behaviors for dementia risk reduction
Time frame: baseline, 2 months (end of treatment), 4 months, 12 months
Body Weight
body weight
Time frame: baseline, 2 months (end of treatment), 4 months, 12 months
Waist circumference
waist circumference (cm)
Time frame: baseline, 2 months (end of treatment), 4 months, 12 months
Lipid panel
Obtained via fasting blood draw. Total cholesterol, HDL cholesterol, LDL cholesterol, triglycerides.
Time frame: baseline, 2 months (end of treatment), 4 months, 12 months
Systolic blood pressure
systolic blood pressure (average of 3 measurements)
Time frame: baseline, 2 months (end of treatment), 4 months, 12 months
Hemoglobin A1C
Glycated hemoglobin, a measure of average blood sugar over the past 2-3 months
Time frame: baseline, 2 months (end of treatment), 4 months, 12 months
Plan to share: Yes — All de-identified IPD will be shared, consistent with the NIH Data Management and Sharing Policy
Supporting information: Study protocol, Statistical analysis plan
No publications or documents are linked to this record.
Start is estimated for Feb 2027; primary completion for Feb 2031, 47 months later.
Of 882 non-industry interventional studies with no phase under Alzheimer Disease, half reached primary completion within 30 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 51. This study's planned 47 months is above that.
Counting every sponsor, half of 959 studies reached it within 29 months; a quarter within 15 and three quarters within 51.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.